Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Ochsenkühn

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Digestion|December 5, 2008
Defensins and efflux transporters meet their fate in 2008: no major role in the pathogenesis of inflammatory bowel diseaseThomas Ochsenkühn
European Journal of Gastroenterology & Hepatology|July 11, 2006
Reaching out for the causative agent in inflammatory bowel disease: is there evidence for Chlamydia pneumoniae as a pathogenic factor?Julia Seiderer, Thomas Ochsenkühn
Gut|April 21, 2011
Current misunderstandings in the management of ulcerative colitisThomas Ochsenkühn, Geert D'Haens
European Journal of Gastroenterology & Hepatology|October 19, 2004
Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot studyThomas Ochsenkühn, Michael Sackmann, Burkhard Göke
Digestion|August 7, 2004
Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University HospitalJulia Seiderer, Burkhard Göke, Thomas Ochsenkühn
The American Journal of Gastroenterology|August 23, 2002
Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's diseaseThomas Ochsenkühn, Burkhard Göke, Michael Sackmann
MMW Fortschritte Der Medizin|November 13, 2019
[A short and pragmatic guide through diagnostics and therapies of chronic inflammatory bowel diseases]Thomas Ochsenkühn, Daniel Szokodi, Cornelia Tillack
The American Journal of Gastroenterology|December 6, 2012
Indigestion after Digestive Disease Week (DDW): be aware of the "Golden Raspberry Award" at DDW and Cyclospora cayetanensisStephan Brand, Thomas Ochsenkühn, Michael Hogardt
United European Gastroenterology Journal|March 28, 2020
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitisThomas Ochsenkühn, Cornelia Tillack, Daniel Szokodi, et al.
MMW Fortschritte Der Medizin|October 31, 2025
[Chronic inflammatory bowel diseases in general practice]Thomas Ochsenkühn, Cornelia Tillack-Schreiber, Daniel Szokodi, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Digestion|December 5, 2008
Defensins and efflux transporters meet their fate in 2008: no major role in the pathogenesis of inflammatory bowel diseaseThomas Ochsenkühn
European Journal of Gastroenterology & Hepatology|July 11, 2006
Reaching out for the causative agent in inflammatory bowel disease: is there evidence for Chlamydia pneumoniae as a pathogenic factor?Julia Seiderer, Thomas Ochsenkühn
Gut|April 21, 2011
Current misunderstandings in the management of ulcerative colitisThomas Ochsenkühn, Geert D'Haens
European Journal of Gastroenterology & Hepatology|October 19, 2004
Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot studyThomas Ochsenkühn, Michael Sackmann, Burkhard Göke
Digestion|August 7, 2004
Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University HospitalJulia Seiderer, Burkhard Göke, Thomas Ochsenkühn
The American Journal of Gastroenterology|August 23, 2002
Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's diseaseThomas Ochsenkühn, Burkhard Göke, Michael Sackmann
MMW Fortschritte Der Medizin|November 13, 2019
[A short and pragmatic guide through diagnostics and therapies of chronic inflammatory bowel diseases]Thomas Ochsenkühn, Daniel Szokodi, Cornelia Tillack
The American Journal of Gastroenterology|December 6, 2012
Indigestion after Digestive Disease Week (DDW): be aware of the "Golden Raspberry Award" at DDW and Cyclospora cayetanensisStephan Brand, Thomas Ochsenkühn, Michael Hogardt
United European Gastroenterology Journal|March 28, 2020
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitisThomas Ochsenkühn, Cornelia Tillack, Daniel Szokodi, et al.
MMW Fortschritte Der Medizin|October 31, 2025
[Chronic inflammatory bowel diseases in general practice]Thomas Ochsenkühn, Cornelia Tillack-Schreiber, Daniel Szokodi, et al.
Pageof 7